Izadi 2021.

Methods	RCT
Participants	Inclusion criteria: Patients with nonalcoholic fatty liver disease, 20 to 55 years of age, BMI greater than 25 and less than 40 kg/m2, lack of history of alcohol consumption and no evidence of any other acute and chronic disorders of the liver (hepatitis B, C, etc.), biliary disease, autoimmune diseases, cancer, and inherited disorders affecting the liver were included. Exclusion criteria: Any allergic reaction to sour tea supplement, use of antioxidant drugs or any other supplements/drugs that could interfere with the study objectives during the intervention or 3 months before the intervention, weight loss of more than 10% during the study period, breastfeeding or pregnancy, and irregular use of the capsules (consuming less than 80% of capsules delivered to participants during the study).
Interventions	Intervention: 1 capsule of sour tea powder (450 mg capsule containing at least 250 mg of anthocyanin) for 8 weeks Control: 1 placebo capsule (pure microcrystalline cellulose) for 8 weeks
Outcomes	Primary outcomes: Biochemical indices (blood lipids, serum total antioxidant capacity, and liver enzymes) Blood pressure Secondary outcomes: Anthropometric indices (means of body weight, BMI, and waist circumferences)
Notes	Location: Khorshid Hospital in Isfahan, Iran Funding: Isfahan University of Medical Sciences Iranian Registry of Clinical Trials: IRCT20140208016529N3